ICIs such as CTL-associated protein 4 (CTLA-4), programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1), and their inhibitors, have been known as key factors for overcoming the immunosuppressive conditions in patients with malignancies including lung cancer. Here, CD274 is linked to lung cancer.